Most Recent
Making good on its promise to crack down on anti-competitive conduct in the commercial construction sector, the ACCC has initiated proceedings against NQ Cranes alleging the crane company entered an agreement with a competitor to divvy up the market for overhead crane parts and servicing in Brisbane and Newcastle.
Crown Resorts is the target of an investigation by AUSTRAC's enforcement team in connection with its dealings with high-risk customers at its Melbourne casino.
Over-the-counter derivative issuers AGM Markets, OT Markets and Oxifin Tech have been ordered to pay a total of $75 million in penalties after a ruling that they engaged in unconscionable conduct causing losses of over $30 million to unsophisticated investors seeking what a judge called "financial heroin hits".
Financial crimes regulator AUSTRAC will not take legal action against Afterpay over its compliance with anti-money laundering laws, following an external auditor's report that found the buy now, pay later provider had received "incorrect" legal advice from several top-tier law firms about its compliance program.
The ACCC has taken a major wholesale supplier of sporting goods to court for allegedly setting minimum prices for cycling and sporting goods in its agreements with retailers.
The director of the besieged Mayfair investment group will submit a new noteholder proposal to the court in an effort to stave off the winding up of M101 Nominees and salvage his multi-million dollar Dunk Island and Mission Beach investments.
In a win for ASIC, a judge has found that former oil and gas company Antares Energy violated its continuous disclosure obligations by failing to reveal the name of the buyer behind an ill-fated US$254 million acquisition of Texan oil assets.
The Australian Securities and Investments Commission has settled its responsible lending case against Volkswagen's financial services unit with an undertaking from the car financier to repay customers $4.7 million.
The Federal Court has upheld Novartis' appeal of a ruling revoking its patent for an oral form of multiple sclerosis drug Gilenya, after Australian generic drug maker Arrow Pharmaceuticals dropped its opposition to the patent despite prevailing before IP Australia.
Mosaic Brands has taken the Australian Communications and Media Authority to court, alleging a request for documents based on suspected Spam Act violations is invalid.